X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs MYLAN (US) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   MYLAN
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
MYLAN
Dec-14
SUN PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs7014,234-   
Low Rs4332,984-   
Sales per share (Unadj.) Rs110.41,449.5-  
Earnings per share (Unadj.) Rs11.0174.6-  
Cash flow per share (Unadj.) Rs17.2281.1-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs158.8720.5-  
Shares outstanding (eoy) m2,399.26378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x5.12.5 206.2%   
Avg P/E ratio x51.620.7 249.8%  
P/CF ratio (eoy) x32.912.8 256.2%  
Price / Book Value ratio x3.65.0 71.3%  
Dividend payout %18.20-   
Avg Mkt Cap Rs m1,360,0211,365,474 99.6%   
No. of employees `00017.825.0 71.2%   
Total wages/salary Rs m53,6710-   
Avg. sales/employee Rs Th14,890.921,937.2 67.9%   
Avg. wages/employee Rs Th3,017.10-   
Avg. net profit/employee Rs Th1,480.62,642.7 56.0%   
INCOME DATA
Net Sales Rs m264,895548,429 48.3%  
Other income Rs m8,388-3,197 -262.4%   
Total revenues Rs m273,282545,232 50.1%   
Gross profit Rs m56,081136,397 41.1%  
Depreciation Rs m14,99840,280 37.2%   
Interest Rs m5,17623,656 21.9%   
Profit before tax Rs m44,29569,264 64.0%   
Minority Interest Rs m0-284 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4522,913 290.2%   
Profit after tax Rs m26,33866,067 39.9%  
Gross profit margin %21.224.9 85.1%  
Effective tax rate %19.14.2 453.8%   
Net profit margin %9.912.0 82.5%  
BALANCE SHEET DATA
Current assets Rs m316,359482,141 65.6%   
Current liabilities Rs m198,643376,938 52.7%   
Net working cap to sales %44.419.2 231.7%  
Current ratio x1.61.3 124.5%  
Inventory Days Days9578 121.5%  
Debtors Days Days108107 100.4%  
Net fixed assets Rs m213,178126,877 168.0%   
Share capital Rs m2,39919,394 12.4%   
"Free" reserves Rs m378,6060-   
Net worth Rs m381,006272,623 139.8%   
Long term debt Rs m17,721407,272 4.4%   
Total assets Rs m643,0281,098,101 58.6%  
Interest coverage x9.63.9 243.3%   
Debt to equity ratio x01.5 3.1%  
Sales to assets ratio x0.40.5 82.5%   
Return on assets %4.98.2 60.0%  
Return on equity %6.924.2 28.5%  
Return on capital %10.013.6 73.6%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,6730-   
CASH FLOW
From Operations Rs m39,07272,091 54.2%  
From Investments Rs m-33,708-56,853 59.3%  
From Financial Activity Rs m-15,393-18,996 81.0%  
Net Cashflow Rs m-7,359-3,758 195.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.04 Rs / USD

Compare SUN PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare SUN PHARMA With: DR. REDDYS LAB  PIRAMAL ENTERPRISES  GLENMARK PHARMA  PANACEA BIOTECH  TTK HEALTHCARE  



Today's Market

Sensex Ends Flat; IT & Energy Stocks Gain(Closing)

Indian share markets traded on a volatile note throughout the day and ended their session on a flat note. Sectoral indices ended on a mixed note with stocks in the IT sector.

Related Views On News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

More Views on News

Most Popular

Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)

Jan 9, 2019

For the first time, we have recommended a bluechip stock in Smart Money Secrets.

3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)

Jan 11, 2019

The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling

Follow a Super Investor Like This to Multiply Your Wealth(The 5 Minute Wrapup)

Jan 4, 2019

Following a super investor can certainly help build a portfolio and create wealth in the long term.

15 Mistakes to Avoid to Make a Killing in the Markets(Profit Hunter)

Jan 3, 2019

Richa dissects the common mistakes investors make and how to avoid and even take advantage of them.

My First Stock Trading Recommendation For 2019(Profit Hunter)

Jan 10, 2019

My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jan 16, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - DIVIS LABORATORIES COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS